Navigation Links
NuvaRing Blood Clot Lawsuit Filed on Behalf of a California Woman Who Developed a Serious Blood Clot Disorder Allegedly Due to Use of NuvaRing, Reports Alonso Krangle

New York, NY (PRWEB) July 25, 2013

Alonso Krangle’s attorneys have recently filed a NuvaRing blood clot lawsuit against Organon, Merck and other companies on behalf of a woman from California. This case (Case No. 2:13-cv-04195-SDW-MCA) was filed July 9, 2013 in the U.S. District Court of New Jersey and specifically names the defendants to be Organon USA, Inc., N.V. Organon, the Schering Corporation, Merck & Co., Inc., and Merck Sharp & Dohme.

While this NuvaRing blood clot lawsuit case alleges that the plaintiff’s use of NuvaRing caused her to develop a severe blood clot disorder known as deep vein thrombosis, it also contends that Organon and the other defendants knew about but failed to publicly disclose the fact that NuvaRing had a higher risk of blood clot-related complications than oral contraceptives. Additionally, this NuvaRing blood clot lawsuit alleges that the defendants failed to properly safety test NuvaRing and, yet, marketed NuvaRing as a safe and effective birth control medication without warning consumers about the potential risks of severe NuvaRing side effects.

Alonso Krangle’s experienced defective drug attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing blood clot lawsuit evaluations to those who have sustained serious injuries, such as deep vein thrombosis and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing blood clot lawsuit claim with one of the compassionate NuvaRing blood clot lawsuit lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website,

The NuvaRing blood clot lawsuit complaint explains that the plaintiff began using NuvaRing in September 2010. After developing severe leg pain, in August 2011, she sought medical attention and underwent a CT scan. At that time, she was informed that she had developed deep vein thrombosis in her leg. Deep vein thrombosis is serious blood clot disorder in which blood clots become lodged in the body’s deep veins; if these clots break free, they can travel to the heart, brain and/or lungs and cause life-threatening complications. Following this diagnosis, the plaintiff was placed on anticoagulation therapy and was advised to stop using NuvaRing. To this day, the plaintiff is still under anticoagulation therapy and has had to undergo regular follow-up care to monitor her health.

Serious NuvaRing Side Effects

The link between NuvaRing use and the development of serious blood clot disorders like deep vein thrombosis and pulmonary embolism has been reported by many medical researchers within recent years. In fact, in 2012, a study published in the New England Journal of Medicine reported that vaginal rings like NuvaRing could nearly triple women’s risk of developing blood clots, when compared to the risk associated with older birth control pills.
( )

Another study published in May 2012 in the British Medical Journal found that women’s risk of developing blood clots increased at least 6.5 times when using vaginal rings like NuvaRing, as opposed to birth control pills.
( )

Seeming to support the alleged link between NuvaRing use and serious blood clots is information from the FDA’s Adverse Events Reporting System (AERS), which has received more than 5,350 reports of serious adverse events related to NuvaRing use since the drug was first introduced in 1997 (though FDA approval was not granted until 2001). Among the most commonly reported adverse effects that patients reported after NuvaRing use were more than 1,170 incidents of pulmonary embolism and more than 1,150 incidents of thrombosis and deep vein thrombosis. According to the FDA AERS, more than 30 percent of women who reported NuvaRing complications required hospitalization, and approximately 3 percent of NuvaRing complications resulted in death.
( )

About Alonso Krangle LLP And Filing A NuvaRing Side Effect Lawsuit

Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website,

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NuvaRing Lawsuit News: First New Jersey NuvaRing Trial Scheduled to Start This Week, Rottenstein Law Group LLP Reports
2. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
3. Alleged NuvaRing Blood-Clotting Lawsuits Update: Resource4thePeople Reports Important Hearing Scheduled for July
4. DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits
5. Latest Court Records Show 6% Increase In NuvaRing Lawsuits, DrugRisks Notes
6. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
7. DrugRisks Update: Use of NuvaRing Drops Amid Injury Allegations
8. NuvaRing Lawsuits Move Forward, as Federal Judge Rules that Plaintiffs’ Experts May Testify on “Bursts” of Estrogen Allegedly Delivered by NuvaRing, Wright & Schulte LLC
9. First NuvaRing Lawsuits in State, Federal NuvaRing Litigations Set to Head to Trial Later This Year, Alonso Krangle LLP Reports
10. Rescheduling of First NuvaRing Lawsuit Trials in State, Federal NuvaRing Lawsuit Litigation, Reports Wright & Schulte LLC
11. 2013 NuvaRing Blood-Clotting Allegations Inquiries Eligible for Review by Resource4thePeople Attorneys
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: